Ruzic, D.; Djoković, N.; Srdić-Rajić, T.; Echeverria, C.; Nikolic, K.; Santibanez, J.F.
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics 2022, 14, 209.
https://doi.org/10.3390/pharmaceutics14010209
AMA Style
Ruzic D, Djoković N, Srdić-Rajić T, Echeverria C, Nikolic K, Santibanez JF.
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics. 2022; 14(1):209.
https://doi.org/10.3390/pharmaceutics14010209
Chicago/Turabian Style
Ruzic, Dusan, Nemanja Djoković, Tatjana Srdić-Rajić, Cesar Echeverria, Katarina Nikolic, and Juan F. Santibanez.
2022. "Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention" Pharmaceutics 14, no. 1: 209.
https://doi.org/10.3390/pharmaceutics14010209
APA Style
Ruzic, D., Djoković, N., Srdić-Rajić, T., Echeverria, C., Nikolic, K., & Santibanez, J. F.
(2022). Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics, 14(1), 209.
https://doi.org/10.3390/pharmaceutics14010209